According to FutureWise analysis, the Liquid Biopsy Market in 2023 is US$ 5.1 billion, and is expected to reach US$ 19.84 billion by 2031 at a CAGR of 18.52%. The growing demand for non-invasive diagnostic methods in oncology is boosting the use of liquid biopsies, which enable early cancer detection and real-time treatment monitoring. Advances in circulating tumor DNA (ctDNA), exosome analysis, and next-generation sequencing (NGS) are enhancing the accuracy and application of these methods across different cancer types.
A liquid biopsy is a less intrusive alternative to surgical biopsies, making it possible to find a tumor with a small blood sample. The most effective therapy for a patient can be determined by looking for DNA traces of the malignancy in the patient's blood. Non-small cell lung cancer (NSCLC) is diagnosed via liquid biopsies, which are also used to screen for NSCLC and as a companion diagnosis for other malignancies, including gastrointestinal, colorectal, breast, prostate, and ovarian cancer. The primary market expansion drivers include liquid biopsy's low cost and efficacy compared to other diagnostic techniques. Growth potential will be continued by fast-track approvals from regulatory agencies, including the US Food and Drug Administration (FDA), for non-invasive cancer detection tests. The market is also expanding due to increased clinical studies to create innovative liquid biopsy assays. Due to its growing use as a prognostic and diagnostic tool, it has excellent potential for market expansion.
Liquid biopsy tests are utilized in various healthcare and research contexts, including hospitals, doctors' offices, pathology labs, and research labs, to better understand the molecular characteristics of cancer. It is a non-invasive blood test that could help physicians, surgeons, and researchers better understand a patient's disease profile and determine the most effective course of treatment to improve cancer patients' survival odds. A simple blood draw, blood plasma nucleic acid extraction, and molecular target amplification are often the first steps in this rapid technique, which enables an examination of the defined biomarkers. Liquid biopsies have several advantages that improve patient safety and the efficiency of cancer therapy, such as simple, non-invasive access to the tumor genome, early cancer identification and detection, characterization of new lesions, and earlier diagnosis of cancer.
FutureWise Market Research has published a report that provides an insightful analysis of liquid biopsy market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry.
According to the analysis conducted by FutureWise research analysts, the liquid biopsy market is estimated to register a considerable growth rate over the forecast period. This report lists the market segments and potential prospects available across this industry, in addition providing crucial information on the total valuation currently held by the industry. Moreover, this report will assist key management individuals in an organisation to enhance their decisions pertaining to business expansion as well as strategic changes for increasing customer base.